Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell-free chromatin particles (cfChPs) are fragments of DNA and histones released into the circulation and extracellular space during cell death via apoptosis or necrosis (Mittra et al., 2012, J. Biosci.). These particles act as damage-associated molecular patterns (DAMPs), capable of entering healthy cells to induce double-strand DNA breaks, genomic instability, and inflammatory cytokine production (Mittra et al., 2015, Ann. Oncol.). In oncology, cfChPs are implicated in the progression of metastasis and the development of therapy-related toxicities by damaging healthy tissue (Inderjit et al., 2021, Front. Genet.). In acute inflammatory states like sepsis and COVID-19, elevated levels of cfChPs contribute to the cytokine storm and multi-organ dysfunction (Raghuram et al., 2021, PLoS One). Therapeutic interventions aim to degrade these particles using DNase I or a combination of Resveratrol and Copper (R-Cu), which generates oxygen radicals to destroy the chromatin structure (Mittra et al., 2017, Free Radic. Biol. Med.). Such treatments have shown promise in reducing systemic inflammation and preventing cancer recurrence in preclinical models. Beyond cancer and sepsis, cfChPs are being investigated for their role in autoimmune diseases and diabetes-related complications (Pal et al., 2021, Sci. Rep.).
Enzymatic or oxidative degradation of extracellular DNA and histone components to neutralize their activity as damage-associated molecular patterns (DAMPs) and prevent their uptake by healthy cells.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell-free chromatin particle (cfChP).